HCV Treatment
3. Better Options for Treating HCV Genotype 3 and Advanced Liver Disease
- Details
- Category: HCV Treatment
- Published on Wednesday, 30 December 2015 00:00
- Written by Liz Highleyman
This year saw the emergence of new and better treatment options for people with hepatitis C virus (HCV) genotypes other than 1 and for those with advanced liver disease.
AASLD 2015: U.S. Faces Biggest Burden of Hepatitis C Treatment Costs Before 2020
- Details
- Category: HCV Treatment
- Published on Wednesday, 09 December 2015 00:00
- Written by Keith Alcorn
The cost of treating hepatitis C is likely to decline dramatically over the next decade in the U.S., not because of cuts in drug prices, but because the population in need of treatment will shrink by 2020 as a majority of patients will already have been treated, according to research by Jagpreet Chhatwal of Massachusetts General Hospital and colleagues presented at the AASLD Liver Meeting in San Francisco last month.
AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 25 November 2015 00:00
- Written by Liz Highleyman
Hepatitis C patients who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir standard therapy, according to results from the SYNERGY study presented at the 2015 AASLD Liver Meeting last week in San Francisco. A related analysis showed that emergence of certain drug-resistance mutations was common during very short therapy, but this did not appear to compromise response to retreatment.
AASLD 2015: Grazoprevir/ Elbasvir Cures More than 90% of People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 04 December 2015 00:00
- Written by Liz Highleyman
Merck's grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C coinfection, was well-tolerated, and did not appear to interact with antiretrovirals, according to final results from the C-EDGE Co-infection study presented at the 2015 AASLD Liver Meeting last month in San Francisco. These results confirm that HIV/HCV coinfected people respond as well to interferon-free therapy as those with HCV alone.
AASLD 2015: HCV Triple Regimen Cures Rapid Responders in 3 Weeks
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 24 November 2015 00:00
- Written by Liz Highleyman
Response-guided therapy using an all-oral regimen of 3 direct-acting antivirals cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from the small SODAPI pilot study, presented in a late-breaking poster at the AASLD Liver Meeting last week in San Francisco. Further research will be needed to see if these promising results hold for larger patient populations.
More Articles...
- AASLD 2015: Study Reveals Potential Challenges for Scaling Up Hepatitis C Therapy in the UK
- Coverage of the 2015 AASLD Liver Meeting
- AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
- AASLD 2015: Daclatasvir + Sofosbuvir Works Well for Genotype 3 HCV Patients with Advanced Disease
Web Design and Development by